Equities Analysts Offer Predictions for KYTX FY2025 Earnings

Key Points

• HC Wainwright has revised Kyverna Therapeutics' FY2025 earnings estimate downward to ($3.60) per share, from a previous estimate of ($3.56), while maintaining a "Buy" rating and a $5.00 price target.
• Kyverna's latest earnings report showed an EPS of ($0.97) for the quarter, surpassing the consensus estimate of ($1.00) by $0.03.
• Institutional investors and hedge funds now hold 18.08% of Kyverna Therapeutics' stock, with significant recent purchases including Gilead Sciences acquiring a stake worth approximately $15.4 million.

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) - Research analysts at HC Wainwright decreased their FY2025 earnings per share (EPS) estimates for shares of Kyverna Therapeutics in a note issued to investors on Wednesday, August 13th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($3.60) per share for the year, down from their prior forecast of ($3.56). HC Wainwright currently has a "Buy" rating and a $5.00 price objective on the stock. The consensus estimate for Kyverna Therapeutics' current full-year earnings is ($3.29) per share. HC Wainwright also issued estimates for Kyverna Therapeutics' Q4 2025 earnings at ($0.82) EPS and FY2026 earnings at ($3.61) EPS.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.00) by $0.03.

Separately, William Blair initiated coverage on Kyverna Therapeutics in a research note on Wednesday. They set an "outperform" rating for the company. One investment analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $15.60.

Kyverna Therapeutics Stock Up 3.9%

Shares of Kyverna Therapeutics stock traded up $0.13 during trading hours on Friday, reaching $3.43. 234,223 shares of the stock traded hands, compared to its average volume of 371,038. The company has a 50 day moving average price of $3.44 and a 200 day moving average price of $2.79. The firm has a market capitalization of $148.33 million, a price-to-earnings ratio of -0.93 and a beta of 3.05. Kyverna Therapeutics has a one year low of $1.78 and a one year high of $8.78.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of KYTX. Geode Capital Management LLC boosted its position in shares of Kyverna Therapeutics by 21.7% during the 4th quarter. Geode Capital Management LLC now owns 539,682 shares of the company's stock valued at $2,019,000 after acquiring an additional 96,370 shares during the last quarter. Wells Fargo & Company MN raised its holdings in Kyverna Therapeutics by 16.4% during the 4th quarter. Wells Fargo & Company MN now owns 179,012 shares of the company's stock valued at $670,000 after buying an additional 25,225 shares during the period. Renaissance Technologies LLC purchased a new stake in Kyverna Therapeutics during the 4th quarter valued at $167,000. Barclays PLC raised its holdings in Kyverna Therapeutics by 27.7% during the 4th quarter. Barclays PLC now owns 89,586 shares of the company's stock valued at $336,000 after buying an additional 19,419 shares during the period. Finally, Gilead Sciences Inc. purchased a new stake in Kyverna Therapeutics during the 4th quarter valued at $15,432,000. 18.08% of the stock is currently owned by institutional investors.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.